The Finnish study in Redox Biology demonstrates that clinically approved HIF-PHIs inhibit cell growth and angiogenesis independently of HIF-1α/HIF-2α through redox metabolism modulation. This in vitro mechanistic work, while promising, remains far from randomized controlled trials and lacks disclosed sample sizes or conflict-of-interest statements beyond academic affiliations. Mainstream coverage frames the finding as serendipitous dual benefit for anemic cancer patients, yet overlooks the established pattern of low-cost repositioning seen with metformin in oncology and statins in multiple disease areas. Earlier observational cohorts, such as those tracking erythropoiesis-stimulating agents, already hinted at metabolic off-target effects now confirmed here. The original reporting misses how payer incentives and patent cliffs discourage investment in such generics despite clear public-health upside. Synthesizing this with a 2023 Lancet Oncology review on HIF pathway modulators and a 2024 Nature Reviews Drug Discovery analysis of 200+ repositioned agents reveals consistent underfunding of non-patentable candidates. Clinical validation will require pragmatic trial designs that track both hemoglobin correction and progression-free survival in chronic kidney disease patients with comorbid malignancy.